Results 201 to 210 of about 31,523 (247)

A Plant Photoregulator‐Inspired S‐Type Heterojunction System for Diabetic Keratopathy via Tri‐Modal Light‐Driven Immunometabolic Reprogramming, Tissue Repair, and Antibacterial Activity

Advanced Science, EarlyView.
To address the multifaceted imbalance in diabetic keratopathy, a light‐responsive biomimetic platform (WCNx‐Rh2) is developed and integrates glucose degradation, immune modulation, and antibacterial defense through a designed heterojunction and screened immunomodulator. WCNx‐Rh2 reduces AGEs/ROS and inflammatory signaling, reprogramming dendritic cells
Mengzhen Zhao, Zhibin Zhou, Yuxuan Wei, Xiangfan Huang, Zhiyong Zhou, Jiaheng Chen, Haoxin Cheng, Xiaotian Hu, Xiaolei Wang   +8 more
wiley   +1 more source

Immunological barriers and engineering strategies for CAR-T cell therapy in acute myeloid leukemia. [PDF]

Front Immunol
Wang Y, Yu T, Wang M, Yu L.
europepmc   +1 more source

A Pancreatitis‐Inspired Trypsinogen Nanoplatform Reprograms Tumor‐Associated Macrophages via NF‐κB for Pancreatic Cancer Immunotherapy

Advanced Science, EarlyView.
Trypsinogen‐loaded nanoparticles reprogram TAMs via NF‐κB/NLRP3, driving M2→M1 conversion and potent phagocytosis to unleash antitumor immunity. ABSTRACT Although reprogramming tumor‐associated macrophages (TAMs) represents a promising therapeutic strategy, approaches that are both precise and safe remain scarce.
Lei Cao, Yu He, Wenhao Li, Bo Gong, Han Lin, Jianlin Shi, Yuan Yong, Wencheng Wu   +7 more
wiley   +1 more source

Pre-treatment T cell features and immune-milieu characteristics shape treatment-induced exhaustion and resistance to Blinatumomab in B-cell acute lymphoblastic leukemia. [PDF]

Front Immunol
Corrado F, Blumenberg V, Kazerani M, Wulf J, Straub T, Philipp N, Nixdorf D, Muth A, Rappa G, Petrera A, Scheurer M, Chu CF, Magno G, Zielinski CE, von Bergwelt-Baildon M, Subklewe M, Bücklein V.   +16 more
europepmc   +1 more source

EpCAM+ Extracellular Vesicle PD‐L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response

Advanced Science, EarlyView.
A highly sensitive SERS‐based platform measures PD‐L1 expression on EpCAM+ circulating EVs from cancer patients undergoing immunotherapy. Monitoring dynamic changes after treatment reveals that reduced EpCAM+ EV PD‐L1 levels associate with improved long‐term clinical outcomes, establishing a non‐invasive approach for tracking immune checkpoint ...
Byeonggeol Mun, Jinyoung Kim, Chang Gon Kim, Seokhyeong Go, Mina Han, Yujin Ouck, Soojin Jang, Seong Uk Son, Gamin Kim, Wonrak Son, Eunjung Kim, Min Hee Hong, Ja Hyun Yeo, Eun‐Kyung Lim, Hye Ryun Kim, Seungjoo Haam   +15 more
wiley   +1 more source

Identification of predictive biomarkers for nivolumab efficacy in non-small cell lung cancer through integrated serum lipidomics and proteomics analysis. [PDF]

Front Immunol
Hase H, Takeda Y, Koyama S, Naito Y, Jingushi K, Fukada SI, Tsujikawa K.   +6 more
europepmc   +1 more source

Cerium Nanoparticle‐Mediated Inhibition of the NSUN2/m5C Axis Suppresses Synovial Aggression in Rheumatoid Arthritis

Advanced Science, EarlyView.
A novel epitranscriptomic mechanism in rheumatoid arthritis is uncovered: NSUN2 promotes disease via m5C‐dependent stabilization of ICMT mRNA, fueling the migration and invasion of pathogenic RA FLS. Targeting this axis with engineered nanoparticles (Ce/SAA NPs) effectively inhibits disease progression, presenting a precise therapeutic strategy ...
Ruiru Li, Simin Chen, Huijuan Hu, Shiyao Wu, Jingnan Wang, Kai Sun, Chenxi Peng, Suling Liu, Shuoyang Zhang, Yu Kuang, Wei Chen, Qian Qiu, Liuqin Liang, Yu Wen, Hanshi Xu, Youjun Xiao   +15 more
wiley   +1 more source

Evaluating the Immunological Impact of Hepatitis B Vaccination in Patients with Inflammatory Bowel Disease. [PDF]

Int J Mol Sci
Soleto I, Marin AC, Baldan-Martin M, Bernardo D, Chaparro M, Gisbert JP.   +5 more
europepmc   +1 more source

Editorial: Exploring immunological factors in inner ear disorders: allergy and inflammation. [PDF]

Front Immunol
Szczepek AJ, Van Rompaey V, Hu B.
europepmc   +1 more source